戴维医疗(300314) - 2022 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2022 was ¥140,779,306.15, representing a 13.98% increase compared to the same period last year[5]. - Net profit attributable to shareholders reached ¥40,081,226.28, a significant increase of 19,550.73% year-on-year[5]. - The net profit after deducting non-recurring gains and losses was ¥36,345,815.85, reflecting a 1,240.33% increase compared to the previous year[5]. - The basic earnings per share (EPS) was ¥0.1392, up 19,785.71% from the same period last year[5]. - Total operating revenue for the period reached ¥349,787,104.41, an increase of 7.5% compared to ¥325,808,561.28 in the previous period[17]. - Net profit for the period was ¥75,997,999.34, representing a growth of 12.5% from ¥67,419,638.85 in the previous period[19]. - Basic and diluted earnings per share increased to ¥0.2639 from ¥0.2341, reflecting a rise of 12.5%[19]. - The total comprehensive income for the period was ¥75,997,999.34, an increase of 12.5% from ¥67,419,638.85 in the previous period[19]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,206,557,240.46, an increase of 4.38% from the end of the previous year[5]. - The company's total assets as of September 30, 2022, amount to ¥1,206,557,240.46, an increase from ¥1,155,886,846.70 at the beginning of the year[15]. - The total current assets are reported at ¥889,772,544.00, compared to ¥852,515,793.23 at the start of the year[15]. - The total liabilities increased to ¥168,832,557.97 from ¥165,360,163.55, showing a slight rise of 1.5%[18]. - The total liabilities include accounts payable of ¥63,290,414.37, down from ¥83,933,000.98, a decrease of 24.83%[15]. Cash Flow - Cash flow from operating activities showed a net increase of ¥25,138,368.32, a 187.28% improvement compared to the previous year[10]. - Cash generated from operating activities was ¥362,009,675.13, up from ¥324,679,627.94, indicating a growth of 11.5%[21]. - The net cash flow from operating activities for Q3 2022 was ¥25,138,368.32, a significant improvement compared to a net outflow of ¥28,803,236.80 in Q3 2021[22]. - The company’s cash flow from operating activities showed resilience with a total inflow of ¥383,049,923.84, compared to ¥332,978,786.18 in Q3 2021, representing an increase of approximately 15.0%[22]. - The total cash and cash equivalents at the end of Q3 2022 amounted to ¥431,386,919.15, compared to ¥219,603,384.97 at the end of Q3 2021, showing an increase of approximately 96.3%[23]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 21,150[11]. - The top three shareholders hold a combined 66.06% of the shares, with Chen Zaihong at 24.69%, Chen Yunqin at 21.12%, and Chen Zaiwei at 20.25%[11]. - The total number of restricted shares held by major shareholders is 98,645,952, with no shares released during the reporting period[12]. - The company has no preferred shareholders as of the reporting period[12]. Investments and Expenses - The company reported a significant increase in accounts receivable by 114.87% due to increased credit extended to agents[9]. - Prepayments increased by 238.68% primarily due to higher advance payments for materials and testing fees[9]. - The company experienced a 21.80% increase in net cash flow from investing activities, totaling ¥84,254,695.53[10]. - Research and development expenses were ¥26,677,228.28, slightly down from ¥27,858,075.00, indicating a decrease of 4.2%[18]. - The company reported a financial income of ¥3,166,772.54, compared to ¥2,161,289.14 in the previous period, reflecting a growth of 46.5%[18].